FutureTech II Acquisition Corp. (FTII)
| Market Cap | 65.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 1.35M |
| Shares Out | 5.83M |
| EPS (ttm) | 0.16 |
| PE Ratio | 71.24 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 736 |
| Open | 11.20 |
| Previous Close | 11.20 |
| Day's Range | 11.20 - 11.20 |
| 52-Week Range | 10.76 - 12.20 |
| Beta | -0.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About FTII
FutureTech II Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on business operating in the technology industry, including artificial intelligence (AI), robotic process automation, and other related technology market. FutureTech II Acquisition Corp. was founded in 2021 and is based in New Rochelle, New York. [Read more]
Financial Performance
Financial StatementsNews
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity
New York, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Longevity Biomedical, Inc. (“Longevity” or “Longevity Biomedical”), a biopharmaceutical company focused on advancing new technologies across therapeutics, ...
FutureTech II Acquisition Corp. Confirms Funding and Extension of Period to Complete Initial Business Combination
New Rochelle, NY, May 17, 2023 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (Nasdaq: FTIIU) (the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock ex...
FutureTech II Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants
NEW ROCHELLE, NY / ACCESSWIRE / April 8, 2022 / FutureTech II Acquisition Corp. (Nasdaq:FTIIU) (the "Company"), a blank check company formed for the purpose of effecting a merger, capital stock exchan...